Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2741-2752

  Chen, Lei ^a   Antras, Lucia ^a   Mei, Sheng Duh ^a   Levy, Natalie ^a   Neary, Maureen ^b   O'Brien, Mary E R ^c   Von Pawel, Joachim ^d  

^a ANALYSIS GROUP   (United States)

^b GLAXOSMITHKLINE   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

Clinical trials; Patient Symptom Assessment in Lung Cancer Instrument; Psychometric validation; Small cell lung cancer; Topotecan

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRONBACH ALPHA COEFFICIENT; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; INTERNAL CONSISTENCY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; PSYCHOMETRY; RETROSPECTIVE STUDY; SCORING SYSTEM; TEST RETEST RELIABILITY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PSYCHOMETRICS;

EID: 36348935069     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233331     Document Type: Article

References (26)

1. Bergman B. Psychosocial issues in the treatment of patients with lung cancer. Lung Cancer 1992;8:1-20
2. Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest 2003;123: 97-104S
3. Naughton MJ, Herndon JE, Shumaker SA, et al. The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Qual Life Res 2002;11:235-48
4. Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 2004;9(Suppl 6):14-24
5. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993;29A(Suppl 1):S51-8
6. Hollen PJ, Gralla PJ, Kris MG, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994;73:2087-98
7. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220
8. Aaronson NK, Ahmedzai A, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76
9. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994;30A:635-42
10. Ihde DC, Pass HI, Glatstein E. Small cell lung cancer. Chapter 30 Cancer of the Lung. In Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 5th edn. Philadelphia: Lippincott-Raven, 1997:911
11. Yoo H, Suh C, Kim S, et al. Korean translation and validation of the Functional Assessment of Cancer Therapy-Lung (FACT-L) version 4. Qual Life Res 2006;15:161-6
12. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67
13. Devita VT, Hellman S, Rosenberg SA. Cancer: Principles & Practice of Oncology, 3rd edn. Philadelphia: Lippincott, 1989
14. Guttman L. Some necessary conditions for common factor analysis. Psychometrika 1954;19:149-61
15. Kaiser HE. The application of electronic computers to factor analysis. Educ Psychol Meas 1960;20:141-51
16. Kaiser HE. A note on Guttman's lower bound for the number of common factors. Br J Stat Psychol 1961;14:1
17. Kline P. A handbook of psychological testing. London: Routiedge, 1993
18. Ware JE, Jr., Harris WJ, Gandek B, et al. MAP-R for Windows: Multitrait/Multi-Item Scale Analysis Software. Boston, MA: Health Assessment Lab, 1997
19. Nunnally JC. Psychometric Theory, 2nd edn. New York: McGraw-Hill, 1978
20. Shrout PE, Fleiss JL. Intraclass correlation: use in assessing rater reliability. Psychol Bull 1979; 86:420-8
21. Lin, LI-K. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-68
22. Cohen, Jacob. Statistical Power Analysis for the Behavioral Sciences, Revised edn. New York: Academic Press, 1977
23. Svensson E. Comparison of the quality of assessments using continuous and discrete ordinal rating scales. Biom J 2000;42:417-34
24. Guyatt GH, Townsend M, Berman LB, Keller JL. A comparison of Likert and visual analogue scales for measuring change in function. J Chron Dis 1987;40:1129-33
25. Hollen PJ, Gralla RJ, Kris MG, et al. A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life? Qual Life Res 2005;14:837-47
26. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. Draft guidance. Washington, DC: Food and Drug Administration/Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research/Center for Devices and Radiological Health, February 2006. Available at: http://www.fda.gov/cder/Guidance/5460dft.pdf [Last accessed 26 August 2007]